Table 8 Sensitivity analysis results for a time horizon of 2 years: variation of HPV prevalence
From: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
Prevalence | Additional tests* versus Aptima, n = | Additional costs versus Aptima, € |
|---|---|---|
Lower value (10.5%) | ||
Hybrid Capture® 2 | 265,652 | 354,096,906.62 €** |
Cobas® 4800 | 276,698 | 2,868,712.91 € |
Higher value (25.4%) | ||
Hybrid Capture® 2 | 243,924 | 540,093,540.88 €** |
Cobas® 4800 | 230,360 | 2,387,698.92 € |